MedTrace Logo

Predictive Determinants of Nephrotic Syndrome Remission in Patients With At-risk Polymorphism of APOL1

NCT06443034 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 124

Last updated 2024-06-05

No results posted yet for this study

Summary

This is a multicentric retrospective observational cohort study.

As primary objective, the study aims to evaluate the factors associated with nephrotic syndrome remission in patient with nephrotic syndrome, biopsy-prove minimal change disease or focal segmental glomerulosclerosis, and an at-risk variant of the APOL1 gene.

As secondary objectives, this study aims:

* To evaluate the benefit of corticosteroids in obtaining the remission of nephrotic syndrome
* To identify the predictors of complete renal remission of nephrotic syndrome
* To evaluate the benefit of corticosteroids in reducing the incidence of end-stage renal disease
* To assess the adverse events of corticosteroids in patients treated with corticosteroids.

Conditions

  • Nephrotic Syndrome
  • Focal Segmental Glomerulosclerosis
  • APOL1 Associated Kidney Disease

Sponsors & Collaborators

  • Assistance Publique - Hôpitaux de Paris

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06443034 on ClinicalTrials.gov